Home ›
Leukemia Trials ›
NCT06537843
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Phase 2 clinical trial to evaluate the combination of venetoclax, cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia.
Trial Details
NCT ID NCT06537843
Phase PHASE2
Sponsor Hospital Municipal São José
Status RECRUITING
Cancer Type Leukemia
Interventions Venetoclax Cytarabine Injection Metformin
Locations (sample) Belém, Brazil|-1.45583,-48.50444 Curitiba, Brazil|-25.42778,-49.27306 Florianópolis, Brazil|-27.59667,-48.54917 Jaú, Brazil|-22.29639,-48.55778 Joinville, Brazil|-26.30444,-48.84556
Key Eligibility Criteria
Diagnosis of AML in accordance with the World Health Organization criteria. Ineligibility for induction chemotherapy due to age (≥ 70 years) or, for patients 18 to 74 years of age, ECOG-PS 2 or 3, creatinine clearance below… Projected life expectancy of at least 12 weeks. Not requiring supplemental oxygen or substitutive renal therapy.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →